These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32306527)

  • 21. Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.
    Mease PJ; Signorovitch J; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani PM
    Dermatology; 2010; 220(1):1-7. PubMed ID: 19940437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquired hemophilia A and fulminant diabetes mellitus possibly caused by adalimumab in a patient with psoriatic arthritis.
    Yamaguchi T; Itoh M; Umezawa Y; Asahina A; Hanabusa H; Nakagawa H
    J Dermatol; 2017 Mar; 44(3):e3-e4. PubMed ID: 27206322
    [No Abstract]   [Full Text] [Related]  

  • 23. A single-centre, observational, retrospective, real-life study evaluating adalimumab biosimilar ABP 501 in the treatment of plaque-type psoriasis and psoriatic arthritis in originator-naïve patients and in patients undergoing non-medical switch from originator.
    Giunta A; Zangrilli A; Bavetta M; Manfreda V; Pensa C; Bianchi L
    Curr Med Res Opin; 2021 Jul; 37(7):1099-1102. PubMed ID: 34011212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical use of ZRC3197 (Adalimumab Biosimilar) in Patients with Inflammatory Arthritis: A Real-life Experience.
    Sharma B
    J Assoc Physicians India; 2017 May; 65(5 Suppl):22-25. PubMed ID: 28836747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
    Hercogová J; Papp KA; Chyrok V; Ullmann M; Vlachos P; Edwards CJ
    Br J Dermatol; 2020 Feb; 182(2):316-326. PubMed ID: 31206593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a preliminary composite disease activity index in psoriatic arthritis.
    Mumtaz A; Gallagher P; Kirby B; Waxman R; Coates LC; Veale J D; Helliwell P; FitzGerald O
    Ann Rheum Dis; 2011 Feb; 70(2):272-7. PubMed ID: 21115550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe subcutaneous hematoma in a patient with psoriatic arthritis: Changes of platelet count in psoriatic patients with biologic agents.
    Maya Y; Fujita Y; Nakayama C; Kitamura S; Hata H; Arita K; Shimizu H
    J Dermatol; 2017 Dec; 44(12):1385-1388. PubMed ID: 28733978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort.
    Popescu CC; Mogoșan CD; Enache L; Codreanu C
    Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557052
    [No Abstract]   [Full Text] [Related]  

  • 29. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.
    Ahn CS; Dothard EH; Garner ML; Feldman SR; Huang WW
    J Am Acad Dermatol; 2015 Sep; 73(3):420-8.e1. PubMed ID: 26184440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa.
    Ricceri F; Rosi E; Di Cesare A; Pescitelli L; Fastame MT; Prignano F
    Dermatol Ther; 2020 Nov; 33(6):e14387. PubMed ID: 33030281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis.
    Emery P; Suh CH; Weinblatt ME; Smolen JS; Keystone EC; Genovese M; Vencovsky J; Kay J; Hong E; Baek Y; Ghil J
    Scand J Rheumatol; 2020 Sep; 49(5):361-370. PubMed ID: 32468892
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient.
    Lindsey SF; Weiss J; Lee ES; Romanelli P
    J Drugs Dermatol; 2014 Jul; 13(7):869-71. PubMed ID: 25007373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The confidence of rheumatologists about switching to biosimilars for their patients.
    Goll GL; Haavardsholm EA; Kvien TK
    Joint Bone Spine; 2018 Oct; 85(5):507-509. PubMed ID: 29631065
    [No Abstract]   [Full Text] [Related]  

  • 34. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.
    Weinblatt ME; Baranauskaite A; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Baek I; Ghil J
    Arthritis Rheumatol; 2018 Jun; 70(6):832-840. PubMed ID: 29439289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
    Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
    Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis.
    Ghil J; Zielińska A; Lee Y
    Curr Med Res Opin; 2019 Mar; 35(3):497-502. PubMed ID: 30561229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction?
    Rallis E; Korfitis C; Stavropoulou E; Papaconstantis M
    J Dermatolog Treat; 2010 Jan; 21(1):3-5. PubMed ID: 19701844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches.
    Blauvelt A; Lacour JP; Fowler JF; Weinberg JM; Gospodinov D; Schuck E; Jauch-Lembach J; Balfour A; Leonardi CL
    Br J Dermatol; 2018 Sep; 179(3):623-631. PubMed ID: 29917226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab.
    Borrás-Blasco J; Gracia-Perez A; Nuñez-Cornejo C; Rosique-Robles JD; Mateu-Puchades A; Casterá MD; Rubio-Fabra M
    J Clin Pharm Ther; 2008 Jun; 33(3):321-5. PubMed ID: 18452420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.